SIRT3 and graft versus host disease: A recent report indicated that T cells from Sirt3-deficient (Sirt3−/−) donor mice caused reduced graft-versus-host disease (GVHD) severity in comparison to T cells from control donor mice, suggesting that Sirt3 targeting can improve transplant recipient outcome.